Search Results

SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC << Back SWOG S2012 - Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung CLINICALTRIALS.GOV IDENTIFIER: NCT05058651 DRUG/TREATMENT: Atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) PHASE: II/III STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=3YGASJXkSxI Dr. David Zhen Discusses SWOG S2012 Immunotherapy (atezolizumab) DESCRIPTION: This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here . CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. Principal Investigator: David B. Zhen, MD Southwest Oncology Group

DAREON™-7: DLL3 for Advanced Neuroendocrine Cancers << Back DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT06132113 DRUG/TREATMENT : BI 764532, Carboplatin, Etoposide, Cisplatin PHASE : 1 STATUS : Recruiting SPONSOR : Boehringer Ingelheim https://www.youtube.com/watch?v=tSN7eS8fJPw DESCRIPTION: This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has 2 parts. Part A of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC. Participants get different doses of BI 764532 as an infusion into a vein. In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it. Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Boehringer Ingelheim EMAIL: clintriage.rdg@boehringer-ingelheim.com PHONE: 1-800-243-0127 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. OTHER HELPFUL RESOURCES:

CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen << Back CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen IDENTIFIER ( ClinicalTrials.gov ) : NCT07087054 DRUG/TREATMENT : Paltusotine PHASE : 3 STATUS : Recruiting SPONSOR : Crinetics Pharmaceuticals Inc. https://www.youtube.com/watch?v=b6Jnzj9Epng CAREFNDR Presentation Slides .pdf Download PDF • 1.60MB DESCRIPTION: A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. MORE INFORMATION Download the CAREFNDR flyer here >>> For more information about the CAREFNDR clinical study, visit CAREFNDR.com/ncf . Global enrollment in CAREFNDR is expected throughout 2025 and 2026. Read this recent press release: " Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome" CONTACT Crinetics Clinical Trials EMAIL: clinicaltrials@crinetics.com PHONE: 833-276-4636 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Go back to the Podcast page EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES Download the transcript here: LACNETS Podcast Episode 27 Transcript .pdf Download PDF • 206KB ABOUT THIS EPISODE What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr. Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. MEET DR. XAVIER KEUTGEN Xavier M. Keutgen MD is a board-certified, double-fellowship trained surgeon who specializes in the treatment of gastro, entero, pancreatic neuroendocrine tumors and neoplasms of the thyroid, parathyroid and adrenal glands. A native from Belgium, Dr. Keutgen graduated magna cum laude from the University of Heidelberg Medical School in Germany and completed a general surgery residency and surgical oncology research fellowship at New York Presbyterian Hospital-Weill Cornell Medical Center. He then completed a hepato-pancreato-biliary fellowship at the University Hospital of Zurich in Switzerland as well as an endocrine oncology and surgery fellowship at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Keutgen currently serves as the director of the Neuroendocrine Tumor Program, director of the Endocrine Research Program and co-director of the Von Hippel-Lindau Clinical Care Program at the University of Chicago Medicine . Throughout his career Dr. Keutgen has developed a particular interest in clinical, translational and basic science research. His laboratory specializes in investigating the role of radiation therapy and DNA damage repair in pancreatic, lung and small bowel neuroendocrine tumors, discovering new actionable molecular targets for neuroendocrine tumors, and elucidating new mechanisms of drug delivery for endocrine malignancies. TOP TEN QUESTIONS What is liver NETs? How often do NETs spread? Is it expected that NETs will eventually spread? If the primary tumor was already removed, do you now call this liver NET or do you still refer to it by the primary site of origin – and why? How is this different from liver cancer? What causes NETs to spread? Is there anything that is done to cause NET tumors to spread? Is there anything that can be done to keep them from spreading? How do you determine if surgery is an option? What is involved in evaluating metastases? What scans or labs are needed? How do you decide what the “tumor burden” is? How do you weigh the grade or ki67? How do you weigh tumor size? Is there a cut-off for tumor size or the number of tumors that is too much to operate? How does one decide between surgery versus other options? How often can surgery or other treatments be done? How safe is liver surgery? How do you approach surgery for someone with liver tumors who also has tumors in the tail versus the head of the pancreas? When someone has had a Whipple surgery and later is found to have tumors in the liver, what are the options? What advances in the field are you most excited about? RESOURCES LACNETS Surgery Resources WATCH: LACNETS Surgery Playlist DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the supporters page Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Introducción NETs - La Presentación NETs de Elevador DescargarLa Tarjeta NET Intro La tarjeta NET Intro se puede completar digital o físicamente. (NOTA: Todos los recursos marcados con * están disponibles únicamente en Inglés) ¿QUÉ ES LA PRESENTACIÓN NETS DE ELEVADOR? La “Presentación NETs de Elevador” es una forma de presentarte. La razón por la que se llama de “Elevador" es porque debe ser lo suficientemente breve para poder decirla durante un viaje en elevador. Definimos una “Presentación NETs de Elevador” como una sinopsis de dos oraciones de tus NETs, que puedes comunicar en 30 segundos o menos. Si estuvieras en un elevador con un experto en NETs y solo tuvieras 30 segundos, la “Presentación NETs de Elevador” sería la introducción ideal, es concisa e ilustra claramente las características más importantes que se necesitan saber sobre tu condición. Esta es tu Introducción NETs, la mejor forma de presentar rápidamente el historial de tus NETs. La “Presentación NETs de Elevador” consta de dos oraciones y contiene la información descrita en las secciones 2 a 6, de la página 1 de NET VITALS. ORACIÓN #1: 1. Tu relación con NETs: Si vives con NETs, puedes comenzar la oración con: “Estoy viviendo con…”. “Me diagnosticaron…”. Si eres cuidador o ser querido de alguien que vive con NETs, puedes comenzar la oración con: “Mi cónyuge/hijo/padre/pariente/amigo/otro pariente vive con…”. “Mi cónyuge/hijo/padre/pariente/amigo/otro pariente fue diagnosticado con…”. Nota: Porque creemos que las palabras tienen poder, no aconsejamos identificarte como paciente o decir que estas enfermo. En su lugar, alentamos el uso de "Estoy viviendo con" o "Me diagnosticaron" o "Me diagnosticaron tal año con..." o incluso "Tengo...". Algunas personas incluso dicen "Estoy viviendo bien con..." porque da el mensaje de que las personas con NETs pueden tener una vida plena. 2. Diferenciación tumoral: Esto es "bien diferenciado" o "poco diferenciado". Se refiere a qué tan anormales se ven las células bajo el microscopio, en comparación con las células sanas circundantes 3. Grado del tumor: Puede ser grado 1, 2 o 3. El grado se refiere a la rapidez con la que se dividen las células tumorales. Si conoces tu ki-67 puedes agregarlo, ya que determina el grado del tumor. El ki-67 lo puedes encontrar en el reporte de patología, estos reportes se realizan cada vez que se extrae tejido de tu cuerpo, generalmente por medio de una biopsia o una cirugía. Es importante aclarar que el grado es diferente a la etapa o estadio, estas ultimas se refieren a qué tanto se ha desplazado el cáncer desde el sitio original del tumor. Es fácil confundir grado con etapa, pero en realidad dicen cosas muy diferentes. El público en general está familiarizado con la estatificación, porque es una forma común de describir un cáncer y da una idea de la prognosis de una persona. Sin embargo, es importante recordar que con el Cáncer Neuroendocrino, la etapa 4 no significa lo mismo que la etapa 4 de otros tipos de cáncer. Tenga en cuenta que los NETs pulmonares no están clasificados por grado, se clasifican en: Carcinoma Típico, Carcinoma Atípico, Carcinoma Neuroendocrino de Células Grandes y Carcinoma de Células Pequeñas. Los Feocromocitomas y los Paragangliomas tampoco se clasifican por grado. Vea esta infografía detallada* del podcast NETWise de NETRF sobre los NETs de pulmón Nuestros recursos de NETs de Pulmón se pueden encontrar aquí* NETWise Infographic Stage, Differentiation & Grade, courtesy of Neuroendocrine Tumor Research Foundation - Download Here 4. Estado funcional del tumor: Puede ser funcional o no funcional. Esto significa específicamente si los tumores producen hormonas (funcionales) o no producen hormonas (no funcionales) y no es indicación de la presencia de síntomas, ya que los síntomas pueden ser producidos por una variedad de razones. 5. Sitio de origen del tumor y metástasis: El sitio de origen es donde se origina el Tumor Primario y es el que define el tipo de NETs (NETs Pancreáticos (pNETs), NETs de Intestino Delgado, NETs de Pulmón, NETs de Colon, etc.) Metástasis es cualquier otro lugar (órgano diferente al Sitio Primario) en donde se encuentren mas tumores del mismo tipo que el Tumor Primario (por ejemplo en el hígado, los huesos, etc.) El sitio de origen será siempre el mismo, aún después de haber extirpado el tumor primario e incluso al no tener ya evidencia de la condición. Una de las razones por las que identificar el sitio de origen (Tumor Primario) es importante, es que le permite a tu equipo médico determinar y evaluar las opciones de tratamiento disponibles y aplicar las más adecuadas para cada caso. 6. Año en el que recibiste el diagnóstico. Este es opcional. ORACIÓN #2: La oración #1 es la base principal. Una vez que hayas dominado la oración #1, entonces (y solo entonces) estarás listo para agregar la oración #2. A la mayoría de nosotros nos resulta más fácil la oración #2 porque estamos familiarizados con los tratamientos y los procedimientos hemos recibido. La oración #2 consiste en eso, es un resumen breve de tus cirugías y tratamientos. La clave aquí es ser conciso. Estos son ejemplos de la oración #2: “A mi esposo lo operaron y le están dando un análogo de somatostatina (lanreotida u octreotida), terapia dirigida al hígado y PRRT” “Me hicieron una resección intestinal en Diciembre del 2022 y me están dando inyecciones Lanreotida, 120mg cada 28 días” ¡Ahí está! Tu historial en una breve Introducción NETs de dos oraciones, en 30 segundos o menos. Si bien puede parecer simple, sabemos que construir tu “Presentación NETs de Elevador” puede presentar ciertos retos. Además, se necesita algo de trabajo y práctica para poder pronunciar tu “Presentación NETs de Elevador” cómodamente. ¡Escríbela, tenla a mano y practica, practica, practica ! Mientras mas lo repitas, más cómodo te sentirás al decirlo y, en poco tiempo, lo podrás decir de una manera muy natural. ¿CUÁLES SON LOS BENEFICIOS DE APRENDER LA “PRESENTACIÓN NETS DE ELEVADOR”? Al aprender a "hablar NET" estarás en la misma página que un experto en NETs. Al decir tu “Presentación NETs de Elevador”, estás comunicando los elementos críticos que los expertos o tu equipo médico necesitan saber para tomar decisiones de tratamiento. Es importante que CONOZCAS Y COMPRENDAS TU CONDICIÓN y no dependas únicamente de tu equipo médico para eso. Aprender a hablar NET te ayuda a saber qué información o tratamientos son relevantes para tu caso. Al participar en reuniones educativas, podrás interpretar y entender mejor la información. Al buscar ensayos clínicos * , es posible que te ayude a determinar cuales son los mas apropiados para ti. Podrás comunicar los elementos esenciales de tus NETs de manera concisa, clara y eficiente. Comunicar los elementos críticos de la condición de una manera eficaz, nos permite tener una mejor utilización del tiempo y esto nos da una mejor oportunidad de hablar sobre tratamientos o de obtener respuestas a nuestras preguntas. Ya sea en un grupo de apoyo, con otras personas viviendo con NETs, con tu equipo médico o al conocer a un experto en NETs en una conferencia, la “Presentación NETs de Elevador” te ayudara a comunicar clara y eficazmente toda la información importante de tu condición, contenida también en tus NET VITALS*. ¿QUÉ NO DEBE ESTAR EN TU NET INTRO? Las palabras tienen poder. Desalentamos el uso de las palabras “Paciente” o “Enfermo” al referirnos a nuestra persona o a nuestros seres queridos. Preferimos el uso de palabras que empoderen y que muestren que nos vemos como personas completas y que no somos definidos por una enfermedad. Ten en cuenta que tu “Presentación NETs de Elevador’ no es lo mismo que tu historia. Hay momento y lugar para contar la historia de tu diagnóstico y de el impacto personal que ha causado. La “Presentación NETs de Elevador” no reemplaza tu historia, es una habilidad diferente, con un propósito diferente. ¡El conocimiento es poder! En esta montaña rusa, donde a veces podemos sentir que todo esta fuera de control, esto es algo que podemos controlar. Aprender tu “Presentación NETs de Elevador” te ayuda a comunicarte en el idioma de los expertos de NETs. Al cerrar las brechas de conocimiento y comprender los términos y conceptos fundamentales de NET, podemos ser mejores pacientes, cuidadores, promotores o defensores. ¡¡Crea tu “Presentación NETs de Elevador” y aprendamos juntos a hablar NET!! DescargarLa Tarjeta NET Intro La tarjeta NET Intro se puede completar digital o físicamente. *Original site translated by Michel DeQuevedo from NETs Mexico . Recursos Si no está seguro de lo qué significan los términos anteriores o de cómo encontrar la diferenciación, el grado o el ki-67 en su informe patológico, le recomendamos los siguientes recursos: Infografía NETWise de NETRF "Etapa, diferenciación y grado"* Episodio 1 del podcast NETWise de NETRF: Lo que tienes que saber sobre los NETs * Seminario web: NET VITALS (a partir de 14:20 minutos) * Seminario web de patología * a cargo de la Dra. Sue Chang (a partir de las 36:43) Video: Manejo de Síntomas * por la Dra. Del Rivero (habla de tumores funcionales y manejo del síndrome carcinoide) NOTA: NET Intro es un documento solo para uso personal. LACNETS no lo envía ni lo recopila. Es un documento que debe completar y llevar a su cita con el médico. Este documento está destinado únicamente a fines informativos y educativos y no reemplaza el asesoramiento médico profesional. Siempre consulte con su médico o proveedor de atención médica.

<< Back Additional Resources WATCH "Understanding Alpha & the Evolving PRRT Landscape" with Dr. Udhayvir Singh Grewal https://www.youtube.com/watch?v=_dE7__jhf9I Download Presentation Slides >>> "2024 Updates on Clinical Trials in Neuroendocrine Tumors" with Dr. Heloisa Soares - April 25, 2024 - LACNETS Patient Educational Event https://www.youtube.com/watch?v=Cdk8uoqKWe0 "Navigating Clinical Trials: Expectations vs Realities" with Taymeyah Al-Toubah, MPH - August 2023 LACNETS Patient Educational Event https://www.youtube.com/watch?v=CXW71vedhIw "The Latest in NET Clinical Trials" - 2023 LACNETS Patient Education Conference https://www.youtube.com/watch?v=h0MFa7jcR4k "Clinical Trials: Why, What & How" - 2023 LACNETS Patient Education Conference https://www.youtube.com/watch?v=Kf3p_j5tFVU "Patient Story & Understanding Clinical Trial Terminology" - 2020 LACNETS Symposium https://www.youtube.com/watch?v=B7XStrrQ6TI "Update on NET Clinical Trials" with Dr. Heloisa Soares - March 2023 LACNETS Educational Event https://www.youtube.com/watch?v=HHtDAQzDj9E "How Clinical Practice Has Been Changed by Clinical Trials in the Last 10 Years" by Dr. Enrique Grande (Credit: INCA) https://www.youtube.com/watch?v=lFyrU7idFUA In this 2022 recording for INCA, Dr. Enrique Grande, MD, PhD, MSc, gives a snapshot of NET research, how clinical trials inform clinical practice, and highlights key trials. "Practice Changing Research in NETS" by Prof. Jonathan R. Strosberg, President of NANETS (Credit: INCA) https://www.youtube.com/watch?v=wWdJfxX5eDs In this 2022 recording for INCA, Prof. Strosberg discusses the current NET clinical trials. "What is the Role of Patients in Trial Design and Efficacy" by Prof. Michael Michael (Credit: INCA) https://www.youtube.com/watch?v=JM1K7ZnXlCo In this 2022 recording for INCA, Prof. Michael discusses the gaps in current NET research and the role of patients in clinical trials design. LISTEN Visit the podcast episode page for more resources >>> Visit the podcast episode page for more resources >>> READ "Why Participate in Clinical Trials?" Clinical Trials Glossary "How to Prepare for Clinical Trials" Info Sheet Glossary: Common Terms in Clinical Trials Navigating Clinical Trials: Expectations vs Realities - Slides from August 19, 2023 LACNETS Educational Event

<< Go Back to NCF Events Page No registration required. HOW TO JOIN THE VIRTUAL LUNCHEON Submit your general questions for the Live Q&A on YouTube OR Facebook via chat. Click Here to Join on YouTube Stream Click Here to Join on Facebook Live “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — who present on topics relevant to neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join with their lunch break. Live sessions are recorded and will be available afterward. ABOUT JAYDIRA DEL RIVERO, MD Endocrinologist & Medical Oncologist National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

<< Back Targeted Therapies Oral Targeted Therapies STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Antibody Drug Conjugate (ADC) Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors ZL-1310 (DLL3-targeted ADC) in DLL3+ Tumors DLL-3 DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

< Back to the upcoming events page LACNETS is hosting an in-person NET Educational Event for patients and caregivers in Minneapolis, Minnesota on Saturday, September 21st from 1:30-5:00 PM. Join us for an afternoon of NET information, connecting and networking. This program has been uniquely designed to maximize the opportunity to engage with NET specialists with two Q&A sessions. LOCATION W Minneapolis - The Foshay 821 S Marquette Ave, Minneapolis, MN 55402 For patients attending the LACNETS in-person NET Educational Event on Saturday, September 21st at the W Minneapolis – The Foshay, parking is available on-site. Please park with valet upon arrival and visit the registration desk to receive your parking validation ticket. At the time of departure, simply hand your validation ticket to the valet for complimentary parking. AGENDA Time Topic Speaker 1:30 - 2 PM Registration 2 - 2:10 PM Welcome LACNETS Team 2:10 - 2:55 PM Patient Panel with 4 NET patients Moderated by Lisa Yen, Patient Advocate & Caregiver, LACNETS 2:55 - 3:45 PM Q&A with NET Experts Chandrikha Chandrasekharan, MBBS, Medical Oncologist, University of Iowa Philip Boudreaux, MD, FACS, Surgical Oncologist, Louisiana State University 3:45 - 4 PM Break 4 - 4:20 PM Overview of Treatments Emil Lou, MD, Medical Oncologist, University of Minnesota 4:20 - 4:40 PM Sequencing of Treatments Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 4:40 - 5 PM Q&A with a NET Expert Panel Emil Lou, MD, Medical Oncologist, University of Minnesota Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic Patrick McGarrah, MD, Medical Oncologist, Mayo Clinic Ajay Prakash, MD, Medical Oncologist, University of Minnesota Donna D'souza, MD, Interventional Oncologist, University of Minnesota Philip Boudreaux, MD, Surgeon, Louisiana State University Moderated by Lisa Yen, Patient Advocate & Caregiver, LACNETS The North American Neuroendocrine Tumor Society (NANETS) is hosting their Regional NET Education Event for medical providers. Help raise awareness and knowledge of neuroendocrine cancer in the medical community by telling your local healthcare professionals to attend the NANETS Regional NET Education Event on Saturday, September 21st. This event will not be broadcast or recorded. If you are newly diagnosed, or need a refresher on NET terms and basics, we encourage you to watch Dr. Chandrasekharan’s presentation “Understanding NET Diagnosis” from our 2024 LACNETS Patient Conference . SPEAKERS: Chandrikha Chandrasekharan, MBBS Medical Oncologist, University of Iowa Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at University of Iowa. She did her initial medical training in India at Kilpauk Medical College. She moved to the USA to complete her internal medicine residency at University of Florida College of Medicine at Jacksonville. Dr. Chandrasekharan is board certified in Medical Oncology and Palliative Medicine. After completing medical oncology fellowship at LSU Shreveport, she pursued an additional year of advanced oncology training in gastrointestinal malignancies at Mayo Clinic. Dr. Chandrasekharan's clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. Thorvardur R. Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson currently serves as President for the North American Neuroendocrine Tumor Society (NANETS). Emil Lou, MD, PhD, FACP Medical Oncology, University of Minnesota Emil Lou, MD, PhD, FACP, is a medical oncologist and neuro-oncologist who provides adult patients with cancer care and treatment through chemotherapy, targeted therapy, and other tailored treatments. In addition to expertise in neuroendocrine tumors, he also specializes in helping patients with gastrointestinal cancers, paraneoplastic disorders, and solid tumor metastases to the brain. He sees patients at the University of Minnesota's Masonic Cancer Clinic at the main campus in Minneapolis. Dr. Lou is also a Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota Medical School. J. Philip Boudreaux, MD, FACS Surgical Oncologist, Louisiana State University J. Philip Boudreaux, MD, FACS, has been recognized for his outstanding contributions to the medical field. He is currently the Professor of Surgery at Louisiana State University Health Sciences Center School of Medicine in New Orleans, LA. Dr. Boudreaux educates medical students and provides high-quality care to patients. While he has held that role for over 20 years, he has spent the last 38 years expanding his knowledge and skills in liver, pancreas, kidney transplantation, organ donation, hepatobiliary and pancreatic surgery, radio frequency ablation of liver tumors, neuroendocrine tumors and carcinoids. His most recent new treatment for metastatic hepatic tumors includes Histotripsy, the destruction of tumor non-invasively with ultrasound. Dr. Boudreaux instituted the liver and pancreas transplant programs at LSU, performed the first pancreas transplant in Louisiana, and initiated the liver and kidney transplant programs at Children’s Hospital, New Orleans. He served as the Director of Liver/Pancreas/Kidney Transplant Services at LSU and Children’s Hospital pre-Katrina. Dr. Boudreaux has spoken publicly at a variety of conferences and educated residents regarding transplant and other related topics. He has published over 75 peer-reviewed publications. Dr. Boudreaux has operated upon over 2,000 patients with neuroendocrine tumors. His center continues to innovate, do research, and often finds ways to turn “inoperable” into “opportunity”. His patients enjoy some of the highest long term survival rates reported in the world’s literature to date. The NOLANETS program has expanded to include East Jefferson Hospital in partnership with the Louisiana Children’s Hospital Medical Network hospitals and the Joe Yenni Cancer Center. In his free time, Dr. Boudreaux enjoys sailing, playing music, fishing, hunting, amateur radio (call sign W5AY), and teaching. He has been a member of the Military Auxiliary Radio System (MARS) since 1968. He attributes his achievements to his education and his work ethic instilled by his parents and mentors. Patrick McGarrah, M.D. Medical Oncologist, Mayo Clinic Dr. Patrick W. McGarrah is a medical oncologist in Rochester, Minnesota and is affiliated with Mayo Clinic-Rochester. Dr. McGarrah specializes in head and neck, neuroendocrine, and gastrointestinal cancers. He received his medical degree from University of Minnesota Medical School and completed his training in 2023. Dr. McGarrah has expertise in treating neuroendocrine tumors, with special interest in poorly differentiated neuroendocrine carcinoma and NETs of the head and neck. Ajay Prakash, MD, PhD Medical Oncologist, University of Minnesota Dr. Ajay Prakash is a medical oncologist specializing in gastrointestinal malignancies. His research is focused on understanding the relationship between the tumor microenvironment, prognosis, and treatment response, with a specific focus on the role of the microbiome in this process. A better understanding of the microbiome, the community of organisms that reside in most human tissues, may allow us to better tailor treatments and offer patient specific guidance on cancer prevention. Clinically, Dr. Prakash is committed to healthcare equity and the delivery of high-quality, academic medicine to historically underserved communities. Donna D'souza, MD Interventional Radiologist, University of Minnesota Donna D’Souza MD, FSIR is an Associate Professor of Radiology and Interventional Radiologist at theUniversity of Minnesota, as well as the Interventional Radiology Medical Student Clerkship Director at the University of Minnesota. Her clinical interests are interventional oncology (especially treating cancers in the liver), portal hypertension interventions, thyroid interventions and women’s health. Dr D’Souza was born and raised in Australia. She completed her medical school at Monash University, and her Radiology Residency and Master of Medicine degree at University of Melbourne in Australia. She subsequently completed a Vascular and Interventional Radiology fellowship at the University of Toronto, followed by Interventional Radiology and Body Radiology fellowships at the University of Minnesota. In her free time she enjoys travelling the world with her husband, hiking, yoga, learning and speaking Japanese, indoor gardening, and spending time with her two dogs. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. REGISTER

< Back to the upcoming events page WATCH THE RECORDING HERE Read highlights from the event in this blogpost >>> The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, held on Sunday, November 9th. ABOUT Hear presentations from local NET experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Post-Event Reception. This event is made possible by the generosity of donors and sponsors. SPEAKER BIOS LOCATION The Robert and Judi Prokop Newman Alumni Center 6200 San Amaro Dr., Coral Gables, FL 33146 AGENDA Download the program >>> *Subject to change. Please check back closer to the event for the most accurate agenda. Time Topic Speaker 8:30 - 9 AM Registration & Breakfast 9 - 9:10 AM Welcome Neuroendocrine Cancer Foundation Team & Dr. Aman Chauhan 9:10 - 9:25 AM Demystifying Clinical Trials Taymeyah Al-Toubah 9:25 - 9:40 AM Role of Surgery in NETs Dr. Jashodeep Datta 9:40 - 9:50 AM Liver-Directed Therapy Dr. Lindsay Thornton 9:50 - 10:10 AM Q&A Faculty; Moderated by Dr. Aman Chauhan 10:10 - 10:30 AM Break 10:30 - 10:45 AM Targeted Therapies & Chemotherapy Dr. Udhayvir Grewal 10:45 - 11 AM PRRT for NETs Dr. Boris Naraev 11 - 11:15 AM Managing Side Effects of Systemic Therapy Dr. Jason Starr 11:15 - 11:30 AM The Latest in Managing Carcinoid Syndrome Dr. Jason Starr 11:30 - 11:45 AM Role of Advocacy in Advancing Care for Neuroendocrine Cancer Dr. Estelamari Rodriquez 11:45 - 12:30 PM Q&A Faculty; Moderated by Dr. Aman Chauhan 12:30 - 1:30 PM Lunch 1:30 - 1:35 PM A NET Patient Journey Aramís Lorié 1:35 - 2:10 PM The Future of NETs: Emerging Therapies & Clinical Trials Dr. Aman Chauhan 2:10 - 2:30 PM Nutrition & Fitness in Cancer Tracy Crane, PhD, RDN 2:30 - 2:45 PM Documentary Trailer 2:45 - 3 PM Closing Neuroendocrine Cancer Foundation Team 3 - 4:30 PM Networking Reception with Live Music Presentation Slides 1_Altoubah.Taymeyah_Demystifying Clinical Trials .pdf Download PDF • 6.51MB 2_Datta-SurgeryNET-110925 Jashodeep Datta .pdf Download PDF • 2.40MB 3_Thorton.Lindsey_Liver Directed Therapy .pdf Download PDF • 1.95MB 4_Grewal_Role of Targeted Therapy & Chemotherapy .pdf Download PDF • 3.29MB 5_Naraev_PRRT for NETs .pdf Download PDF • 3.90MB 6_Starr.Jason_Managing Side Effects of Systemic Therapy_NCF .pdf Download PDF • 337KB 7_Starr.Jason_Carcinoid Syndrome .pdf Download PDF • 401KB 8_Rodriguez.Estelamari _Role of Advocacy in Advancing Care for Neuroendocrine Cancer_ .pdf Download PDF • 7.47MB The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers << Back DAREON™ 5: DLL-3 BiTE for Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT05882058 DRUG/TREATMENT : BI 764532 PHASE : 2 STATUS : Recruiting SPONSOR : Boehringer Ingelheim https://www.youtube.com/watch?v=tSN7eS8fJPw https://www.youtube.com/watch?v=nSDnIMQP2EQ DESCRIPTION: Boehringer Ingelheim is sponsoring DAREON™ -5, a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Boehringer Ingelheim EMAIL: clintriage.rdg@boehringer-ingelheim.com PHONE: 1-800-243-0127 Visit this patient-friendly website for the DAREON-5 clinical trial program for more information>>>